64,300 Shares in Artivion, Inc. $AORT Bought by Bridger Management LLC

Key Points

• Bridger Management LLC acquired 64,300 shares of Artivion, Inc. valued at approximately $1.58 million, increasing its stake to 0.15% and making AORT its 25th largest holding.
• Artivion's quarterly earnings exceeded expectations with an EPS of $0.24, beating the consensus estimate of $0.11, and reporting a revenue of $112.97 million, up 15.3% year-over-year.
• Multiple analysts have upgraded their ratings on AORT, with a consensus rating of "Buy" and an average target price of $40.63, reflecting positive sentiment towards the stock's performance.

Bridger Management LLC purchased a new stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 64,300 shares of the company's stock, valued at approximately $1,580,000. Artivion comprises 0.8% of Bridger Management LLC's portfolio, making the stock its 25th largest position. Bridger Management LLC owned approximately 0.15% of Artivion as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Legacy Advisors LLC acquired a new position in shares of Artivion in the first quarter valued at approximately $28,000. MCF Advisors LLC grew its holdings in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion in the fourth quarter valued at approximately $64,000. Raymond James Financial Inc. acquired a new position in shares of Artivion in the fourth quarter valued at approximately $275,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Artivion in the first quarter valued at approximately $284,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Artivion from a "hold" rating to a "buy" rating in a report on Monday, August 25th. LADENBURG THALM/SH SH cut shares of Artivion from a "buy" rating to a "neutral" rating and lifted their price objective for the company from $32.00 to $38.80 in a report on Wednesday, August 13th. Canaccord Genuity Group lifted their price objective on shares of Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 8th. Stifel Nicolaus lifted their price objective on shares of Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, JMP Securities lifted their price target on shares of Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Artivion presently has a consensus rating of "Buy" and a consensus price target of $40.63.

Artivion Stock Down 1.4%

Shares of AORT traded down $0.61 during mid-day trading on Friday, reaching $43.42. The company's stock had a trading volume of 371,694 shares, compared to its average volume of 612,873. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $45.07. The stock has a market cap of $2.05 billion, a PE ratio of -103.39 and a beta of 1.70. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The company's 50 day moving average is $36.34 and its 200 day moving average is $29.79.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $112.97 million for the quarter, compared to the consensus estimate of $107.96 million. The business's revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Equities analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Activity at Artivion

In other news, insider John E. Davis sold 10,802 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the sale, the insider owned 208,778 shares in the company, valued at approximately $9,117,335.26. The trade was a 4.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jean F. Holloway sold 10,000 shares of the business's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.37, for a total transaction of $443,700.00. Following the sale, the senior vice president owned 172,129 shares of the company's stock, valued at $7,637,363.73. This represents a 5.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 115,990 shares of company stock worth $4,435,823 over the last 90 days. 7.60% of the stock is owned by corporate insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.